| Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESS Newswire / May 9, 2025 / The following abrdn U.S. Closed-End Funds (NYSE:ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW)(NYSE American:FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on May 30, 2025 to all shareholders of record as of May 22, 2025 (ex-dividend date May 22, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on June 30, 2025, to all shareholders of record as of May 22, 2025 (ex-dividend date May 22, 2025). |
accessnewswire.com |
2025-05-09 20:17:00 |
Czytaj oryginał (ang.) |
| The India Fund: Primed For A Rebound |
Indian equities have begun to recover after a torrid few months. Actively managed IFN is positioned to outperform on the way up. Investors get a +10% yield to sit and wait. |
seekingalpha.com |
2025-04-30 19:41:09 |
Czytaj oryginał (ang.) |
| India Fund: Healthy Distributions, But Not Much Else Going For It |
IFN has experienced considerable volatility this year but has managed to outperform other pockets largely due to its distributions. IFN's valuations are not as prohibitive as what it was 8 months back, but its closed-ended peer-IIF and IEMG (a proxy of emerging markets) offer a better earnings valuation tradeoff. Indian banks, which dominate IFN, are suffering from below-par loan growth, and the RBI's shift in stance is likely to put pressure on net interest margins. |
seekingalpha.com |
2025-04-30 19:30:00 |
Czytaj oryginał (ang.) |
| Aberdeen U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESS Newswire / March 31, 2025 / The Aberdeen U.S. Closed-End Funds (NYSE:ASGI, HQH, HQL, IFN, JEQ, THQ), (NYSE American:IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on March 31, 2025, on a per share basis to all shareholders of record as of March 25, 2025 (ex-dividend date March 25, 2025). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) which paid on March 31, 2025, to all shareholders of record as of February 21, 2025 (ex-dividend date February 21, 2025). |
accessnewswire.com |
2025-03-31 20:27:00 |
Czytaj oryginał (ang.) |
| Continue To Prefer IIF Vs. IFN As Challenging Conditions For Indian Stocks Remain |
Investing in Indian stocks via closed end funds like IFN and IIF offers high yields but comes with valuation risks and potential market corrections. IIF has outperformed IFN over various time periods, benefiting from its smaller size and more nimble management, despite trading at a larger discount to NAV. Indian stock market valuations remain high, with local investor enthusiasm potentially waning due to less attractive earnings yields compared to local bonds. |
seekingalpha.com |
2025-02-19 10:08:28 |
Czytaj oryginał (ang.) |
| abrdn U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESS Newswire / February 11, 2025 / The following abrdn U.S. Closed-End Funds (NYSE:ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, JEQ, THQ, THW)(NYSE American:FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on February 28, 2025 to all shareholders of record as of February 21, 2025 (ex-dividend date February 21, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on March 31, 2025 to all shareholders of record as of February 21, 2025 (ex-dividend date February 21, 2025). |
accessnewswire.com |
2025-02-11 18:37:00 |
Czytaj oryginał (ang.) |
| abrdn U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESSWIRE / January 10, 2025 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, HQH, HQL, IFN, JEQ, THQ)(NYSE American:IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on January 10, 2025, on a per share basis to all shareholders of record as of December 30, 2024 (ex-dividend date December 30, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) which paid on January 10, 2025, to all shareholders of record as of November 21, 2024 (ex-dividend date November 21, 2024). |
accesswire.com |
2025-01-10 18:17:00 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For 9% Yield (December 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-12-29 10:30:00 |
Czytaj oryginał (ang.) |
| IFN: Selling May Abate, But Don't Get Too Complacent |
After three successive years of outperforming global stocks, The India Fund (IFN) is on course to reverse that narrative. Relative to the rest of the globe, India's growth prospects still look alluring, but relative to its own lofty standards, questions may be asked. The INR keeps dropping to record lows every other week, and this may dampen enthusiasm from foreign institutions. |
seekingalpha.com |
2024-12-27 15:35:45 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For 8.5% Yield (November 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-11-24 11:30:00 |
Czytaj oryginał (ang.) |
| abrdn U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESSWIRE / November 11, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, JEQ, THQ, THW)(NYSE American:FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on November 29, 2024 to all shareholders of record as of November 21, 2024 (ex-dividend date November 21, 2024). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on January 10, 2025 to all shareholders of record as of November 21, 2024 (ex-dividend date November 21, 2024). |
accesswire.com |
2024-11-11 18:17:00 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For 9.5% Yield (October 2024) |
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-10-27 11:00:00 |
Czytaj oryginał (ang.) |
| India Fund: This 10% Yielder Is Still Worth A Look |
The abrdn-managed India Fund has undergone some changes. But remains a fund well-equipped to navigate turbulence. Patient investors get paid very well to sit and wait. |
seekingalpha.com |
2024-10-20 05:02:20 |
Czytaj oryginał (ang.) |
| abrdn U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESSWIRE / September 30, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, HQH, HQL, IFN, JEQ, THQ)(NYSE American:IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on September 30, 2024, on a per share basis to all shareholders of record as of September 23, 2024 (ex-dividend date September 23, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) which paid on September 30, 2024, to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024), and the abrdn Global Infrastructure Income Fund (ASGI) which paid on September 30, 2024, to all shareholders of record as of September 20, 2024 (ex-dividend date September 20, 2024). |
accesswire.com |
2024-09-30 20:17:00 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For 9% Plus Yield (September 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-09-29 13:30:00 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For Nearly 9% Yield (August 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-08-24 13:00:00 |
Czytaj oryginał (ang.) |
| India Fund: A Most Interesting Large-Cap India Play |
Don't be fooled by the India Fund's headline underperformance. The case to own IFN long-term is as compelling as it's ever been. In the meantime, investors get paid very well to sit and wait. |
seekingalpha.com |
2024-08-11 05:53:08 |
Czytaj oryginał (ang.) |
| abrdn U.S. Closed-End Funds Announce Distribution Payment Details |
PHILADELPHIA, PA / ACCESSWIRE / August 9, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP)(NYSE:ASGI)(NYSE:AWP)(NYSE:HQH)(NYSE:HQL)(NYSE:IFN)(NYSE:JEQ)(NYSE:THQ)(NYSE:THW)(NYSE American:FAX)(NYSE American:FCO)(NYSE American:IAF)(NYSE American:VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 30, 2024 to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on September 30, 2024, to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024). |
accesswire.com |
2024-08-09 20:17:00 |
Czytaj oryginał (ang.) |
| IFN: India Looks Promising, But This May Not Be The Most Ideal CEF |
India's ongoing ascendance in the global landscape is supported by a stable political regime, a prudent central bank, a fast-growing economy, and a young and aspirational middle-class. Whilst there are a plethora of ETFs offering pure-play exposure to Indian equities, IFN is only one out of two CEFs that focuses on India. We gauged the relative structures, the distributions, sector exposure, risk-adjusted return track records, discount to NAVs, valuations, and long-term earnings, and feel that IFN comes up short. |
seekingalpha.com |
2024-08-08 15:44:26 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For Nearly 9% Yield (July 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-07-27 13:00:00 |
Czytaj oryginał (ang.) |
| The India Fund Inc. Announces Payment of Distribution |
PHILADELPHIA, PA / ACCESSWIRE / July 5, 2024 / The India Fund, Inc. ("IFN") (the "Fund"), today announced that the Fund paid the distribution noted in the table below on July 5, 2024, on a per share basis to all shareholders of record as of May 30, 2024 (ex-dividend date May 30, 2024). Ticker Exchange Fund Amount IFN NYSE The India Fund, Inc. $0.4500 The Fund has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital. |
accesswire.com |
2024-07-05 20:17:00 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For A 9% Yield (June 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-06-23 13:00:00 |
Czytaj oryginał (ang.) |
| IFN: Rights Offering Results |
IFN completes its rights offering. A sell and rebuy strategy would have worked once again. IFN is a decent choice for those looking for Indian stock market exposure. |
seekingalpha.com |
2024-05-29 13:21:25 |
Czytaj oryginał (ang.) |
| The India Fund, Inc. Announces Distribution Payment Details |
PHILADELPHIA, PA / ACCESSWIRE / May 20, 2024 / The India Fund, Inc. (NYSE:IFN), announced today that it will pay $0.45 on a per share basis on July 5, 2024 to all shareholders of record as of May 30, 2024 (ex-dividend date May 30, 2024). For The India Fund, Inc. ("IFN"), this stock distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder.TickerExchangeFundAmountIFNNYSEThe India Fund, Inc.$ 0.45At the end of each calendar year, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of the Fund's distributions and provide information with respect to their appropriate tax treatment for the prior calendar year. You should not draw any conclusions about the Fund's investment performance from the amount of the distributions.For The India Fund, Inc. ("IFN"), this stock distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. Shares of common stock will be issued at the lower of the net asset value ("NAV") per share or the market price per share with a floor for the NAV of not less than 95% of the market price. The valuation date for this stock distribution is June 21, 2024. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who will have whole and fractional shares added to their account.Shareholders may request to be paid their quarterly distributions in cash instead of shares of common stock by providing advance notice to the bank, brokerage or nominee who holds their shares if the shares are in "street name," or by filling out in advance an election card received from Computershare Investor Services if the shares are in registered form. To receive the quarterly distribution payable in July 2024 in cash instead of shares of common stock, the bank, brokerage or nominee who holds the shares must advise the Depository Trust Company as to the full and fractional shares for which they want the distribution paid in cash by June 20, 2024, and written notification for the election of cash by registered shareholders must be received by Computershare Investor Services prior to June 20, 2024.The Fund has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital in reliance on an exemptive order granted by the Securities and Exchange Commission.Under applicable U.S. tax rules, the amount and character of distributable income for the Fund's fiscal year can be finally determined only as of the end of the Fund's fiscal year. However, under Section 19 of the Investment Company Act of 1940, as amended (the "1940 Act") and related rules, the Fund may be required to indicate to shareholders the estimated source of certain distributions to shareholders.The following tables set forth the estimated amounts of the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions to be paid as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses on securities and currencies.The Fund's estimated sources of the current distributions to be paid and for its current fiscal year to date are as follows:Estimated Amounts of Current Distribution per ShareFundDistribution AmountNet Investment IncomeNet Realized Short-Term Gains*Net Realized Long-Term GainsReturn of CapitalIFN$0.4500----$0.4500100%--Estimated Amounts of Fiscal Year to Date Cumulative Distributions per ShareFundFiscal Year** to Date Distribution AmountNet Investment IncomeNet Realized Short-Term Gains*Net Realized Long-Term GainsReturn of CapitalIFN$0.8800----$0.8800100%--* includes currency gains**IFN has a 12/31 fiscal year end.The amounts and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations. After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.The following table provides the Fund's total return performance based on net asset value (NAV) over various time periods compared to the Fund's annualized and cumulative distribution rates.Fund Performance and Distribution Rate InformationFundAverage Annual Total Return on NAV for the 5 Year Period Ending 04/30/2024¹Current Fiscal Period's Annualized Distribution Rate on NAV²Cumulative Total Return on NAV¹Cumulative Distribution Rate on NAV²IFN9.08%9.01%9.31%2.25%1 Return data is net of all fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund's dividend reinvestment plan.2 Based on the Fund's NAV as of April 30, 2024.Shareholders should not draw any conclusions about a Fund's investment performance from the amount of the Fund's current distributions or from the terms of the distribution policy (the "Distribution Policy").While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market.Pursuant to an exemptive order granted by the Securities and Exchange Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940 Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held at the date such amount is received.The payment of distributions in accordance with the Distribution Policy may result in a decrease in the Fund's net assets. A decrease in the Fund's net assets may cause an increase in the Fund's annual operating expense ratio and a decrease in the Fund's market price per share to the extent the market price correlates closely to the Fund's net asset value per share. The Distribution Policy may also negatively affect the Fund's investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund's Board has the right to amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy may affect the Fund's market price per share. Investors should consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular circumstances.Circular 230 disclosure: To ensure compliance with requirements imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.In the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Asia Limited, abrdn Private Equity (Europe) Limited, and abrdn ETFs Advisors LLC.Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results.www.abrdnifn.com###For More Information Contact:abrdn U.S. Closed-End FundsInvestor Relations1-800-522-5465Investor.Relations@abrdn.comSOURCE: The India Fund, Inc. |
https://www.accesswire.com |
2024-05-20 20:27:00 |
Czytaj oryginał (ang.) |
| Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target |
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq®) without dose-limiting toxicity at any dose levelCytokine data reveals about 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at any doseClinical benefit was seen at four months post-initiation of dosing in 35% of evaluable patients (8/23) with advanced solid tumors PRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation. SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform, which extends the half-life and activity of the IL-12 component due to binding native albumin in the serum and targets the tumor microenvironment (TME) by strongly binding gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). SB101 is a Phase 1 multiple-ascending dose (MAD) trial in adult patients with advanced solid tumors (NCT05352750) that commenced in Q2 2022 and is currently enrolling the sixth dose cohort. SB221 is a Phase 1b/2a dose-escalation and proof-of-concept study of the combination of SON-1010 with atezolizumab (in collaboration with Genentech, a member of the Roche Group), in a study focused on platinum-resistant ovarian cancer (PROC) (NCT05756907) that started in Q4 2023, now enrolling the fourth dose cohort. In addition, SON-1010 was studied in SB102, which was a Phase 1 single-ascending dose (SAD) trial in healthy volunteers (NCT05408572) that started in Q3 2022; the results were recently published (Kenney, et al, Frontiers in Immunology, 2024).Safety in both of the active cancer trials has been reviewed by their respective Safety Review Committees at each step during dose escalation. Both trials use a ‘desensitizing' first dose to take advantage of the known tachyphylaxis with rhIL-12, which minimizes toxicity and allows higher maintenance doses. No dose-limiting toxicities or related serious adverse events have occurred to date. The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events (AEs) being reported as mild. All have been transient, with no evidence of cytokine release syndrome. Of the 25 cancer patients dosed to date and evaluable for follow-up at this latest cutoff, 15 (60%) had stable disease at their first follow-up scan, 8 of whom were progressing at study entry. At four months follow-up, 8 of 23 evaluable patients remained stable at the second CT scan, suggesting clinical benefit of SON-1010 in 35% of the patients."We have now dosed 18 cancer patients at increasing SON-1010 drug levels in the SB101 study, completed dosing in 31 healthy volunteers in SB102, and are rapidly filling the dose-escalation cohorts with 12 subjects enrolled in the first four cohorts of the SB221 combination study," said Richard Kenney, M.D., Sonnet's Chief Medical Officer. "The overall safety and toxicity profile for SON-1010, primarily including local reactions, headache, myalgia, and fatigue, mimics the published experience with rhIL-12, which prompted us to raise the target dose to enhance potential efficacy. The SB102 study allowed us to generate clean data for the pharmacokinetic (PK) and pharmacodynamic (PD) analyses, enabling simulation of the effect of multiple doses with the help of a continual reassessment model of PK and PD. This modeling suggests target-mediated drug disposition (TMDD), which supports the mechanism of the FHAB being directed to tumor tissue. The combination of SON-1010 with atezolizumab may benefit from the ability of IL-12 to turn ‘cold' tumors ‘hot', which upregulates the amount of PD-L1 in the TME."One patient with progressive endometrial sarcoma receiving SON-1010 monotherapy in SB101 had stable disease (SD) for almost 2 years before progressing - her ascites had resolved and tumors had shrunk at one point but she never reached a partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) rules. Cytokine analysis following each dose in that study revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked at 24 to 48 hours and returned to baseline within 2 to 4 weeks. A small increase in IL-10 was observed with each dose as expected in response to IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα, and there was no indication of any potential for cytokine release syndrome (CRS) at these doses. One patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have received 8 and 10 cycles, respectively, and are continuing on the study. The stable AE profiles despite dose escalation led us to reevaluate the target dose, so the Company has added groups in both studies to evaluate 1200 ng/kg SON-1010 as a maintenance dose (the molar equivalent of 800 ng/kg rhIL-12). Finally, Part 2 of the SB221 combination study has been trimmed to remove the monotherapy arm."The findings to date in these two trials represent significant progress for the SON-1010 molecule", said Robert Wenham, M.D., Chair, Department of GYN Oncology at Moffitt Cancer Center and the Lead Principal Investigator for SB221. "Multiple strategies to present IL-12 safely have been tried over the past two decades with little evidence of improved tolerability in humans, yet the preclinical models continue to suggest that induction of IFNγ in the TME can activate an effective anti-tumor response. This also results in the local induction of PD-L1. Adding a cohort to increase the target MTD of SON-1010, an extended PK molecule that is concentrated in the TME, is the right approach at this stage. This will provide a chance to study the safety of SON-1010 monotherapy in SB101, and then in combination with atezolizumab in SB221, along with the clinical effect of the combination on PROC in a limited set of subjects in the expansion cohort later this year. Defining the best dose for SON-1010 is required to allow a direct randomized comparison of the strategy with the standard of care therapy in Part 2.""We are very pleased with the data we are seeing at these higher dose levels of SON-1010, with safety and tolerability being well within expected levels, as well as displaying SON-1010 extended PK/PD, tumor targeting, and clinical activity during treatment," said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. "Research on rhIL-12 in humans has been hindered by toxicity for decades. We believe that the IL-12 component in SON-1010 is presented in a way that is safer, due to the longer half-life, and it is concentrated in the tumor, due to the recurrent binding of the FHAB-associated albumin to SPARC in the TME. It is important to note that many of these patients have been fighting their cancers for a very long time and have exhausted all approved treatment regimens available to them, so seeing tumor shrinkage at any dose is both difficult to achieve and encouraging for future results. We are excited to continue testing the impact of SON-1010 in combination with atezolizumab at these higher dose levels in patients with PROC, who represent a significant unmet medical need, and we expect to have a further update early next year."About SON-1010SON-1010 is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3. This was selected to bind both at normal pH, as well as at the acidic pH typically found in the TME. The FHAB technology targets tumor and lymphatic tissue, providing a mechanism for dose sparing and an opportunity to improve the safety and efficacy profile of not only IL-12, but a variety of potent immunomodulators that can be added using the platform. Interleukin-12 can orchestrate a robust immune response to many cancers and pathogens. Given the types of proteins induced in the TME, such as the Secreted Protein and Rich in Cysteine (SPARC) and glycoprotein 60 (GP60), several types of cancer such as non-small cell lung cancer, melanoma, head and neck cancer, sarcoma, and some gynecological cancers are particularly relevant for this approach. SON-1010 is designed to deliver IL-12 to local tumor tissue, turning ‘cold' tumors ‘hot' by stimulating IFNγ, which activates innate and adaptive immune cell responses and increases the production of Programed Death Ligand 1 (PD-L1) on tumor cells.About the SB101 Phase 1 TrialThis first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and will be conducted at several sites across the United States. While the optimal dose is unknown at this stage, the potential to target tumors, the extended PK mechanism and our preclinical data suggest the therapeutic dose may be lower compared to native human IL-12. The study, utilizing a standard 3+3 oncology design in at least five cohorts, should establish the MTD and the recommended Phase 2 dose (RP2D) using monthly subcutaneous injections of SON-1010. The primary endpoint explores the safety and tolerability of SON-1010, with key secondary endpoints intended to measure pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity. This study will form the basis for potential combinations with other types of immunotherapies and the future development of bispecific candidates using the FHAB platform.About the SB221 Phase 1b/2a TrialSB221 is a global Phase 1b/2a multicenter, dose-escalation and randomized proof-of-concept study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). The study is designed in Part 1 to rapidly establish the maximum tolerated dose (MTD) of the combination in patients with advanced solid tumors at the lower dose levels. The focus shifts to PROC at higher dose levels using small dose-escalation groups with expansion of the dataset at the recommended Phase 2 dose (RP2D). This would be followed in Part 2 by an assessment in patients with PROC of the potential for improved efficacy of the combination versus the standard of care. Both companies look forward to this collaboration as an opportunity to improve outcomes for patients with ovarian cancer.About Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company's clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Sonnet BioTherapeutics Investor ContactJack YauchSolebury Strategic Communications862-754-1024jyauch@soleburystrat.comSOURCE: Sonnet BioTherapeutics Holdings, Inc. |
https://www.accesswire.com |
2024-05-20 13:15:00 |
Czytaj oryginał (ang.) |
| The India Fund, Inc. (NYSE:IFN) Shares Purchased by National Bank of Canada FI |
National Bank of Canada FI boosted its holdings in shares of The India Fund, Inc. (NYSE:IFN – Free Report) by 233.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,000 shares of the investment management company’s stock after purchasing an additional 1,400 shares during the period. National Bank of Canada FI’s holdings in The India Fund were worth $37,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds also recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. lifted its stake in shares of The India Fund by 33.4% in the 3rd quarter. Atria Wealth Solutions Inc. now owns 215,380 shares of the investment management company’s stock valued at $3,752,000 after purchasing an additional 53,907 shares during the period. International Assets Investment Management LLC acquired a new position in The India Fund in the 4th quarter worth about $669,000. Koshinski Asset Management Inc. boosted its position in The India Fund by 104.9% during the fourth quarter. Koshinski Asset Management Inc. now owns 44,315 shares of the investment management company’s stock worth $811,000 after purchasing an additional 22,687 shares in the last quarter. American Institute for Advanced Investment Management LLP acquired a new stake in The India Fund in the fourth quarter valued at approximately $245,000. Finally, Avantax Advisory Services Inc. purchased a new position in shares of The India Fund during the 3rd quarter valued at approximately $212,000. 10.76% of the stock is owned by hedge funds and other institutional investors. The India Fund Stock Performance IFN opened at $17.92 on Monday. The company has a 50-day moving average price of $19.04 and a 200 day moving average price of $18.75. The India Fund, Inc. has a twelve month low of $15.12 and a twelve month high of $21.25. About The India Fund (Free Report) The India Fund, Inc is a close ended equity mutual fund launched and managed by Aberdeen Standard Investments (Asia) Limited. The fund invests in public equity markets of India. It seeks to invest in stocks of small-cap, mid-cap, and large-cap companies. The fund employs a quantitative and fundamental analysis with a bottom-up stock picking and asset allocation approach to create its portfolio. See Also Five stocks we like better than The India Fund Investing in the High PE Growth Stocks MarketBeat Week in Review – 5/13 – 5/17 How to Invest in Biotech Stocks Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Yield Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 09:06:55 |
Czytaj oryginał (ang.) |
| 5 Best CEFs This Month For A 10% Yield (May 2024) |
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds. |
seekingalpha.com |
2024-05-19 14:00:00 |
Czytaj oryginał (ang.) |